Hcw Biologics Stock Performance
| HCWB Stock | USD 1.05 0.06 6.06% |
The firm retains a Market Volatility (i.e., Beta) of 1.81, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, HCW Biologics will likely underperform. At this point, HCW Biologics has a negative expected return of -1.58%. Please make sure to check out HCW Biologics' value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if HCW Biologics performance from the past will be repeated at future time.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days HCW Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:40 | Last Split Date 2025-04-11 |
1 | Why retail investors favor HCW Biologics Inc. stock - Quarterly Portfolio Review Risk Managed Investment Strategies - newser.com | 11/11/2025 |
2 | HCW Biologics Enters into 4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules | 11/19/2025 |
3 | Hedge Fund Bets Why HCW Biologics Inc. stock is seen as undervalued - Portfolio Growth Summary Weekly Chart Analysis and Guides - moha.gov.vn | 11/28/2025 |
4 | Can HCW Biologics Inc. stock deliver strong Q4 earnings - Market Activity Report Community Trade Idea Sharing - Blm Sonu Canavar | 12/18/2025 |
5 | Acquisition by Byam Rebecca of 20000 shares of HCW Biologics at 2.0316 subject to Rule 16b-3 | 01/08/2026 |
6 | Risk Off Can HCW Biologics Inc stock double in the next year - Portfolio Value Summary Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn | 01/22/2026 |
7 | Acquisition by Peter Rhode of tradable shares of HCW Biologics at 0.14 subject to Rule 16b-3 | 02/02/2026 |
| Begin Period Cash Flow | 3.6 M | |
| Total Cashflows From Investing Activities | -261.6 K |
HCW Biologics Relative Risk vs. Return Landscape
If you would invest 306.00 in HCW Biologics on November 8, 2025 and sell it today you would lose (207.00) from holding HCW Biologics or give up 67.65% of portfolio value over 90 days. HCW Biologics is currently does not generate positive expected returns and assumes 7.5397% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than HCW, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
HCW Biologics Target Price Odds to finish over Current Price
The tendency of HCW Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.05 | 90 days | 1.05 | about 85.74 |
Based on a normal probability distribution, the odds of HCW Biologics to move above the current price in 90 days from now is about 85.74 (This HCW Biologics probability density function shows the probability of HCW Stock to fall within a particular range of prices over 90 days) .
HCW Biologics Price Density |
| Price |
Predictive Modules for HCW Biologics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as HCW Biologics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of HCW Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
HCW Biologics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. HCW Biologics is not an exception. The market had few large corrections towards the HCW Biologics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold HCW Biologics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of HCW Biologics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.86 | |
β | Beta against Dow Jones | 1.81 | |
σ | Overall volatility | 0.73 | |
Ir | Information ratio | -0.25 |
HCW Biologics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of HCW Biologics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for HCW Biologics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| HCW Biologics generated a negative expected return over the last 90 days | |
| HCW Biologics has high historical volatility and very poor performance | |
| HCW Biologics has some characteristics of a very speculative penny stock | |
| HCW Biologics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.57 M. Net Loss for the year was (30.02 M) with profit before overhead, payroll, taxes, and interest of 166.57 K. | |
| HCW Biologics currently holds about 32.41 M in cash with (14.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9. | |
| HCW Biologics has a poor financial position based on the latest SEC disclosures | |
| Roughly 27.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Peter Rhode of tradable shares of HCW Biologics at 0.14 subject to Rule 16b-3 |
HCW Biologics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of HCW Stock often depends not only on the future outlook of the current and potential HCW Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. HCW Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.8 M | |
| Cash And Short Term Investments | 4.7 M |
HCW Biologics Fundamentals Growth
HCW Stock prices reflect investors' perceptions of the future prospects and financial health of HCW Biologics, and HCW Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HCW Stock performance.
| Return On Equity | -277.26 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (528.87) % | ||||
| Current Valuation | 9.52 M | ||||
| Shares Outstanding | 2.15 M | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 8.16 X | ||||
| Revenue | 2.57 M | ||||
| Gross Profit | 166.57 K | ||||
| EBITDA | (27.68 M) | ||||
| Net Income | (30.02 M) | ||||
| Cash And Equivalents | 32.41 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 13.69 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 30.25 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (14.23 M) | ||||
| Earnings Per Share | (16.41) X | ||||
| Market Capitalization | 5.36 M | ||||
| Total Asset | 30.24 M | ||||
| Retained Earnings | (100.56 M) | ||||
| Working Capital | (23.93 M) | ||||
About HCW Biologics Performance
By analyzing HCW Biologics' fundamental ratios, stakeholders can gain valuable insights into HCW Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HCW Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HCW Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 110.80 | 98.49 | |
| Return On Tangible Assets | (1.14) | (1.20) | |
| Return On Capital Employed | (55.79) | (53.00) | |
| Return On Assets | (1.14) | (1.20) | |
| Return On Equity | 3.99 | 4.19 |
Things to note about HCW Biologics performance evaluation
Checking the ongoing alerts about HCW Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HCW Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HCW Biologics generated a negative expected return over the last 90 days | |
| HCW Biologics has high historical volatility and very poor performance | |
| HCW Biologics has some characteristics of a very speculative penny stock | |
| HCW Biologics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.57 M. Net Loss for the year was (30.02 M) with profit before overhead, payroll, taxes, and interest of 166.57 K. | |
| HCW Biologics currently holds about 32.41 M in cash with (14.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9. | |
| HCW Biologics has a poor financial position based on the latest SEC disclosures | |
| Roughly 27.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Peter Rhode of tradable shares of HCW Biologics at 0.14 subject to Rule 16b-3 |
- Analyzing HCW Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HCW Biologics' stock is overvalued or undervalued compared to its peers.
- Examining HCW Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HCW Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of HCW Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HCW Biologics' stock. These opinions can provide insight into HCW Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |